SB 203580
Tocris Bioscience | Catalog # 1202
Product Description
SB 203580 is a selective inhibitor of p38 MAPK (IC50 values are 50 and 500 nM for SAPK2a/p38 and SAPK2b/p38β2 respectively). Displays 100-500-fold selectivity over LCK, GSK-3β and PKBα. Shown to inhibit IL-2-induced T cell proliferation, cyclooxygenase-1 and -2, and thromboxane synthase. Enhances clonal growth of skin epithelial progenitor cells; stimulates neural stem cell (NSC) proliferation. SB 203580 is an essential component of medium for maintaining stem cells in naive pluripotent state and can be used to promote expansion of HSCs ex vivo.
Water-soluble Salt also available.
Product Specifications for SB 203580
Molecular Weight
Formula
Storage
Purity
Chemical Name
CAS Number
PubChem ID
InChI Key
SMILES
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 9.44 | 25 |
Preparing Stock Solutions for SB 203580
The following data is based on the product molecular weight 377.44.
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.25 mM | 10.60 mL | 52.99 mL | 105.98 mL |
| 1.25 mM | 2.12 mL | 10.60 mL | 21.20 mL |
| 2.5 mM | 1.06 mL | 5.30 mL | 10.60 mL |
| 12.5 mM | 0.21 mL | 1.06 mL | 2.12 mL |
Calculators
Background References
References are publications that support the biological activity of the product. See our Citations tab to view 715 publications citing the usage of this product.
- Jiang Effects of signaling pathway inhibitors on hematopoietic stem cells. Mol.Med.Rep. 2021 PMID: 33179097
- Gafni Derivation of novel human ground state naive pluripotent stem cells. Nature 2013 PMID: 24172903
- Sato Inhibitors of p38 mitogen-activated protein kinase enhance proliferation of mouse neural stem cells. J.Neurosci.Res. 2008 PMID: 18338804
- Saklatvala Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen on a thromboxane analogue. J.Biol.Chem. 1996 PMID: 8636072
- Davies Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 2000 PMID: 10998351
- Borsch-Haubold Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. J.Biol.Chem. 1998 PMID: 9786874
Product Documents for SB 203580
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Product Specific Notices for SB 203580
For research use only
Citations for SB 203580
Customer Reviews for SB 203580 (6)
Have you used SB 203580?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Customer Images
-
Species: HumanAssay Type: In VitroVerified Customer | Posted 10/18/2022Combinatorial treatments of the p38 MAPK inhibitor with chemotherapeutics led to synergistic apoptotic phenotype in vitro. The product is highly recommended.
-
Species: HumanVerified Customer | Posted 07/20/2021Product was dissolved in DMSO, and was used at a concentration of 10 µM in a cancer cell line.
-
Species: HumanVerified Customer | Posted 07/01/2021Used MAPK inhibitors at 10 μM: UO126: MEK1/MEK2 inhibitor, SB203580: p38 inhibitor, ZM336372: c-RAF inhibitor.
-
Species: HumanAssay Type: In VitroVerified Customer | Posted 06/10/2021SB 203580 was dissolved in DMSO and used at a final concentration of 1, 3 or 10 µM in human cancer cell lines, followed by treatment with genotoxics.
-
Species: HumanAssay Type: In VitroCell Line/Tissue: A549 or MDAMB231Verified Customer | Posted 07/01/2020We ordered this product, combining with another inhibitor, to confirm the migration.To confirm that tested product induces migration, we also screen all MAPK inhibitors and MIF receptor antagonistsAll MAPK inhibitors (ZM336372: c-RAF inhibitor; UO126: MEK1/MEK2 inhibitor, SB203580: p38 inhibitor) were used at 10 μM
-
Species: MouseAssay Type: In VitroCell Line/Tissue: Primary murine microglia cellsVerified Customer | Posted 06/08/2019The role of MAPK pathways (JNK, p38 and ERK) was studied in the LPA induced pro-inflammatory phenotype in microglia. In this case cells were incubated for the indicated time points with LPA (1µM) in the presence or absence of SB239063 (10µM) or SB203580 (10µM). A series of assays were performed. p38 MAPK inhibition totally decreased the expression of 4 pro-inflammatory transcription factors (here presented: pp65). Both inhibitors worked nicely and the results were consistent.
There are no reviews that match your criteria.